Adanya penurunan fungsi pada ginjal dapat mempengaruhi proses eritropoiesis yang beresiko terjadinya anemia. Prevalensi anemia meningkat seiring meningkatnya stage penyakit ginjal kronik. Penelitian ini untuk melihat gambaran terapi anemia dan luaran klinis terapi eritropoetin pada pasien CKD dengan hemodialisis di RS PKU Muhammadiyah Yogyakarta. Penelitian dilakukan dengan design cohort retrospektif secara observasional-analitik. Kriteria inklusi berupa pasien dengan usia >18 tahun, pasien penyakit ginjal kronik stage 4 dan 5 yang menjalani rawat jalan dan hemodialisis rutin minimal selama 3 bulan dengan kondisi yang stabil, pasien dengan diagnosis anemia normositik normokromik dan mendapatkan terapi anemia berupa eritropoetin, tersedia data rekam medis. Pengumpulan data dilakukan dilakukan selama 3 bulan berdasarkan rekam medis periode Januari – Desember 2020. Analisis statistik independent t-test dilakukan untuk membandingkan perbedaan peningkatan kadar Hb antara eritropoetin alfa dan beta dalam 3 bulan. Terdapat 113 pasien memenuhi kriteria inklusi. Karakteristik pasien didominasi pasien laki-laki (58%); rentang usia 41-60 tahun (44%); CKD stage V (98%); frekuensi hemodialisis 2x setiap minggu (92%); dan terapi menggunakan epoetin alfa (85%). Rata-rata nilai Hb selama 3 bulan pada kelompok epoetin beta (9,51 mg/dl) lebih tinggi dibandingkan pada kelompok epoetin alfa (8,73 mg/dl) dan berbeda signifikan secara statistik (p<0,005).
Chronic kidney disease (CKD) is a condition in which the kidneys are unable to maintain a fluid balance of metabolic waste that is progressive, irreversible, and takes place slowly. Anemia is a complication of CKD that contributes to morbidity, mortality, and quality of life of patients, as well as greater costs of care. This study aims to evaluate the differences in the effectiveness and cost of anemia therapy with epoetin in patients with chronic kidney disease. The study was conducted in an analytical-observational manner with a retrospective cohort design from the provider's perspective. The sample used was CKD patients with anemia who met the inclusion criteria for the period January - December 2020, data were taken from medical records and patient financial recapitulation. Statistical analysis was carried out on the effectiveness of anemia therapy with epoetin based on the achievement of clinical outcomes of increasing Hb values within 3 months and financing calculated based on direct medical costs. A total of 113 patients met the inclusion criteria, consisting of 96 patients in the epoetin alpha group and 17 patients in the epoetin beta group. The percentage of achieving therapeutic targets in the epoetin beta group was higher (11.76%) than in the epoetin alfa group (10.42%). The average increase in Hb in the EPO beta group was higher than in the EPO alpha group. The cost of epoetin for anemia treatment in the beta epoetin group (Rp 1,005,365) was lower than the epoetin alfa group (Rp 1,017,188). The ICER value obtained was IDR -125,966, indicating a cost savings of IDR 125,966 to increase 1% of the achievement of therapeutic targets for Hb values >10 g/dl. The cost of therapy with EPO beta is lower than EPO alpha and the achievement of Hb therapy targets is better in EPO beta than EPO alpha.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.